STOCK TITAN
  1. Home
  2. Sec-filings
  3. ERNA
  4. [EFFECT] Ernexa Therapeutics Inc. SEC Filing

[EFFECT] Ernexa Therapeutics Inc. SEC Filing

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
EFFECT

Rhea-AI Filing Summary

Analyzing...
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Notice of Effectiveness
Effectiveness Date: March 30, 2026 4:30 P.M.
Form: S-3
CIK: 0000748592
Company Name: Ernexa Therapeutics Inc.
File Number: 333-294307

Source: View Original Filing on SEC EDGAR

Ernexa

NASDAQ:ERNA

View ERNA Stock Overview →

ERNA Rankings

#6645 Ranked by Market Cap
N/A Ranked by Dividends

ERNA Latest News

Mar 31, 2026
Ernexa Therapeutics Highlights Key Catalysts as Company Advances Toward First-in-Human Clinical Trials in 2026
Feb 20, 2026
Ernexa Therapeutics to Participate in Virtual Investor Closing Bell Series
Feb 6, 2026
Ernexa Therapeutics Announces Pricing of $10.5 Million Public Offering
Feb 3, 2026
Ernexa Therapeutics Participates in Virtual Investor “What This Means” Segment Highlighting Recent Successful Pre-IND Meeting with U.S. FDA
Jan 27, 2026
Ernexa Therapeutics Selected as One of Only Ten Global Companies for Prestigious JETRO Japan Entry Acceleration Program

ERNA Latest SEC Filings

Mar 24, 2026
[S-3/A] Ernexa Therapeutics Inc. Amended Shelf Registration Statement
Mar 20, 2026
[8-K] Ernexa Therapeutics Inc. Reports Material Event
Mar 13, 2026
[S-3] Ernexa Therapeutics Inc. Shelf Registration Statement
Mar 13, 2026
[10-K] Ernexa Therapeutics Inc. Files Annual Report
Feb 26, 2026
[8-K] Ernexa Therapeutics Inc. Reports Material Event

ERNA Stock Data

5.51M
19.97M
Biotechnology
Pharmaceutical Preparations
Link
United States
CAMBRIDGE